Private Sector Tatsuya Kondo Becomes PMDA Head
This article was originally published in PharmAsia News
Japan's International Medical Center President Tatsuya Kondo became the new chief executive of Japan's Pharmaceuticals and Medical Devices Agency, effective April 1. Kondo is the first person to be appointed to the position who was not previously an administrative officer for Ministry of Health, Labor and Welfare. Kondo's immediate predecessor, former MHLW drug division director Akira Miyajima, resigned from the post on Jan. 17. His resignation is believed to be a sign of taking responsibility for ignoring a list of hepatitis C cases caused by contaminated blood products and failing to notify the patients about the information. (Click here for more - Japanese language
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"